Published in Ann Surg on January 01, 2008
Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology (2008) 3.04
NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas (2010) 3.00
Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut (2011) 2.14
Lymph nodes and survival in pancreatic neuroendocrine tumors. Arch Surg (2012) 1.55
The diversity and commonalities of gastroenteropancreatic neuroendocrine tumors. Langenbecks Arch Surg (2011) 1.21
Insulinoma: pathophysiology, localization and management. Future Oncol (2010) 1.21
Intraoperative localization of insulinoma and normal pancreas using invisible near-infrared fluorescent light. Ann Surg Oncol (2009) 1.16
Predicting patient survival after pancreaticoduodenectomy for malignancy: histopathological criteria based on perineural infiltration and lymphovascular invasion. HPB (Oxford) (2010) 1.10
Enucleation in pancreatic surgery: indications, technique, and outcome compared to standard pancreatic resections. Langenbecks Arch Surg (2011) 1.08
Insulinoma and anaesthetic implications. Indian J Anaesth (2012) 1.03
Insulinoma. Surg Clin North Am (2009) 0.95
The surgical management of insulinomas in children. J Pediatr Surg (2013) 0.94
Surgical management of pancreatic neuroendocrine tumors. Surg Today (2011) 0.93
Analysis of lymph node metastasis in pancreatic neuroendocrine tumors (PNETs) based on the tumor size and hormonal production. J Gastroenterol (2012) 0.91
Insulinoma causing liver metastases 15 years after initial surgery, accompanied by glomerulonephritis. Case Rep Endocrinol (2012) 0.88
Recurrent hypoglycaemia in a type 2 diabetes patient - diagnostic difficulties. Arch Med Sci (2010) 0.87
Insulinoma case series: Experience of a tertiary care center. Indian J Endocrinol Metab (2014) 0.84
Increased rate of clinically relevant pancreatic fistula after deep enucleation of small pancreatic tumors. Langenbecks Arch Surg (2014) 0.82
A case of occult insulinoma localized by pancreatic dynamic enhanced spiral CT. World J Gastroenterol (2010) 0.82
Endoscopic ultrasound (EUS)-guided fiducial placement allows localization of small neuroendocrine tumors during parenchymal-sparing pancreatic surgery. Surg Endosc (2013) 0.80
Endocrine neoplasms in familial syndromes of hyperparathyroidism. Endocr Relat Cancer (2016) 0.78
Gastroenteropancreatic neuroendocrine tumors: indications for and pitfalls of frozen section examination. Virchows Arch (2008) 0.78
Isoattenuating insulinomas at biphasic contrast-enhanced CT: frequency, clinicopathologic features and perfusion characteristics. Eur Radiol (2016) 0.77
Role of preoperative endoscopic ultrasound-guided fine-needle tattooing of a pancreatic head insulinoma. World J Gastrointest Endosc (2014) 0.77
Pancreatic neuroendocrine tumours: hypoenhancement on arterial phase computed tomography predicts biological aggressiveness. HPB (Oxford) (2013) 0.77
Insulinoma After Bariatric Surgery: Diagnostic Dilemma and Therapeutic Approaches. Obes Surg (2016) 0.75
Insulinoma: a comprehensive summary of two cases. J Clin Diagn Res (2014) 0.75
Insulinoma: rare yet important. BMJ Case Rep (2014) 0.75
Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery (2005) 16.42
Ten-year experience with 733 pancreatic resections: changing indications, older patients, and decreasing length of hospitalization. Arch Surg (2001) 4.59
The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann N Y Acad Sci (2004) 4.13
Functioning insulinoma--incidence, recurrence, and long-term survival of patients: a 60-year study. Mayo Clin Proc (1991) 3.88
Insulinoma: clinical and diagnostic features of 60 consecutive cases. Mayo Clin Proc (1976) 2.93
Conservation of the spleen with distal pancreatectomy. Arch Surg (1988) 2.59
Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol (2002) 2.39
Insulinoma. Best Pract Res Clin Gastroenterol (2005) 1.80
Localization and surgical treatment of occult insulinomas. Ann Surg (1990) 1.76
Morbidity and mortality of aggressive resection in patients with advanced neuroendocrine tumors. Arch Surg (2003) 1.70
Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas. Am J Gastroenterol (2000) 1.59
Beta-islet cell tumors of the pancreas: results of a study on 1,067 cases. Surgery (1974) 1.48
Metastatic insulin-secreting carcinoma of the pancreas: clinical course and the role of surgery. Surgery (1984) 1.30
Insulinomas associated with multiple endocrine neoplasia type I: the need for a different surgical approach. Surgery (1991) 1.29
Surgery for benign insulinoma: an international review. World J Surg (1990) 1.21
Selective arterial calcium stimulation and hepatic venous sampling in the evaluation of hyperinsulinemic hypoglycemia: potential and limitations. J Vasc Interv Radiol (2004) 1.19
Pancreatic tissue sampling guided by EUS, CT/US, and surgery: a comparison of sensitivity and specificity. Gastrointest Endosc (2002) 1.19
Localization of insulinomas. Arch Surg (1999) 1.16
Insulinoma--experience from 1950 to 1995. West J Med (1998) 1.15
Intraoperative methods to stage and localize pancreatic and duodenal tumors. Ann Oncol (1999) 1.14
Endoscopic ultrasound in the localisation of pancreatic islet cell tumours. Best Pract Res Clin Endocrinol Metab (2005) 1.11
Preoperative localization of insulinomas is not necessary. J Am Coll Surg (1999) 1.10
Endoscopic ultrasonography and somatostatin receptor scintigraphy in the preoperative localisation of insulinomas and gastrinomas. Gut (1996) 1.10
Surgical approach to insulinomas. Assessing the need for preoperative localization. Arch Surg (1992) 1.08
Blind distal pancreatectomy for occult insulinoma, an inadvisable procedure. J Am Coll Surg (2002) 1.07
Surgical management of insulinoma associated with multiple endocrine neoplasia type I. World J Surg (1995) 1.06
Pancreatic insulinomas. A 15-year experience. Arch Surg (1997) 1.05
Insulinoma: diagnosis, surgical management and long-term follow-up. Review of 41 cases. Am J Surg (1980) 1.01
Gastrointestinal endocrine tumours. Insulinoma. Baillieres Clin Gastroenterol (1996) 0.97
Preoperative imaging versus intraoperative localization of tumors in adult surgical patients with hyperinsulinemia: a multicenter study of 338 patients. World J Surg (1988) 0.96
Surgical treatment of insulinomas. Surg Clin North Am (2004) 0.91
The ultrasonic detection of insulinomas during surgical exploration of the pancreas. World J Surg (1987) 0.91
Cytokeratin 19 is a powerful predictor of survival in pancreatic endocrine tumors. Am J Surg Pathol (2004) 0.88
What preoperative assessment is necessary for insulinomas? Calculating the degree of waste: analysis of 29 cases. Chir Ital (2002) 0.88
Multiple endocrine neoplasia type 1. Endocrinol Metab Clin North Am (2000) 0.84
Pancreatic insulinomas. Am J Surg (1993) 0.81
Combined use of calcium infusion localization and a minimally invasive surgical procedure in the management of insulinoma. Endocr Pract (2004) 0.79
IgG4-related disease. N Engl J Med (2012) 15.76
Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature (2003) 10.33
International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology (2012) 7.22
Diagnosis of pancreatic cystic neoplasms: a report of the cooperative pancreatic cyst study. Gastroenterology (2004) 6.75
Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature (2013) 6.53
Clinicopathologic correlates of solitary fibrous tumors. Cancer (2002) 5.96
Main-duct intraductal papillary mucinous neoplasms of the pancreas: clinical predictors of malignancy and long-term survival following resection. Ann Surg (2004) 5.09
Autoimmune pancreatitis. N Engl J Med (2006) 5.00
Incidental pancreatic cysts: clinicopathologic characteristics and comparison with symptomatic patients. Arch Surg (2003) 4.86
Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res (2010) 4.71
Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab (2008) 4.68
BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res (2013) 4.28
Recommendations for the nomenclature of IgG4-related disease and its individual organ system manifestations. Arthritis Rheum (2012) 4.27
Cystic neoplasms of the pancreas. N Engl J Med (2004) 3.89
Pancreatic ductal adenocarcinoma: long-term survival does not equal cure. Surgery (2012) 3.87
Genome-wide chromatin state transitions associated with developmental and environmental cues. Cell (2013) 3.83
Aberrant overexpression of satellite repeats in pancreatic and other epithelial cancers. Science (2011) 3.77
Hepatic portal venous gas: the ABCs of management. Arch Surg (2009) 3.76
mTORC1 in the Paneth cell niche couples intestinal stem-cell function to calorie intake. Nature (2012) 3.51
In vivo lineage tracing defines the role of acinar-to-ductal transdifferentiation in inflammatory ductal metaplasia. Gastroenterology (2007) 3.41
Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol (2006) 3.37
Isolation and characterization of centroacinar/terminal ductal progenitor cells in adult mouse pancreas. Proc Natl Acad Sci U S A (2009) 3.25
A novel somatic mouse model to survey tumorigenic potential applied to the Hedgehog pathway. Cancer Res (2006) 3.06
Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist (2011) 3.05
Branch-duct intraductal papillary mucinous neoplasms: observations in 145 patients who underwent resection. Gastroenterology (2007) 2.96
Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic disease. Arthritis Rheum (2010) 2.90
Rituximab for the treatment of IgG4-related disease: lessons from 10 consecutive patients. Medicine (Baltimore) (2012) 2.84
Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg (2015) 2.79
Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors. Proc Natl Acad Sci U S A (2012) 2.66
Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype. Clin Cancer Res (2009) 2.62
The impact of the 80-hour resident workweek on surgical residents and attending surgeons. Ann Surg (2006) 2.59
Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set. Am J Surg Pathol (2010) 2.56
Intraepithelial lymphocytosis in architecturally preserved proximal small intestinal mucosa: an increasing diagnostic problem with a wide differential diagnosis. Arch Pathol Lab Med (2006) 2.46
Mucinous cystic neoplasm of the pancreas is not an aggressive entity: lessons from 163 resected patients. Ann Surg (2008) 2.45
STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis. Cancer Res (2011) 2.35
Autoimmune pancreatitis: imaging features. Radiology (2004) 2.34
Serous cystadenoma of the pancreas: tumor growth rates and recommendations for treatment. Ann Surg (2005) 2.27
Pancreatic ductal adenocarcinoma: is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a "true" R0 resection? Ann Surg (2013) 2.26
American Surgical Association Blue Ribbon Committee Report on Surgical Education: 2004. Ann Surg (2005) 2.25
Implications and cost of pancreatic leak following distal pancreatic resection. Arch Surg (2006) 2.25
Incidental pancreatic cysts: do we really know what we are watching? Pancreatology (2010) 2.22
Case records of the Massachusetts General Hospital. Case 16-2008. A 46-year-old woman with bone pain. N Engl J Med (2008) 2.21
Inhibition of gamma-secretase activity inhibits tumor progression in a mouse model of pancreatic ductal adenocarcinoma. Gastroenterology (2009) 2.17
PTEN is a major tumor suppressor in pancreatic ductal adenocarcinoma and regulates an NF-κB-cytokine network. Cancer Discov (2011) 2.14
Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol (2011) 2.13
Identification of surgical complications and deaths: an assessment of the traditional surgical morbidity and mortality conference compared with the American College of Surgeons-National Surgical Quality Improvement Program. J Am Coll Surg (2006) 2.07
Case Records of the Massachusetts General Hospital. Case 25-2014. A 37-year-old man with ulcerative colitis and bloody diarrhea. N Engl J Med (2014) 2.06
Plectin-1 as a novel biomarker for pancreatic cancer. Clin Cancer Res (2010) 2.03
Branched chain in situ hybridization for albumin as a marker of hepatocellular differentiation: evaluation of manual and automated in situ hybridization platforms. Am J Surg Pathol (2015) 2.02
Case records of the Massachusetts General Hospital. Case 33-2012. A 34-year-old woman with episodic paresthesias and altered mental status after childbirth. N Engl J Med (2012) 2.00
Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw (2012) 1.97
Residency training in surgery in the 21st century: a new paradigm. Surgery (2004) 1.94
Prognosis of invasive intraductal papillary mucinous neoplasm depends on histological and precursor epithelial subtypes. Gut (2011) 1.94
False-negative core needle biopsies of the breast: an analysis of clinical, radiologic, and pathologic findings in 27 concecutive cases of missed breast cancer. Cancer (2003) 1.92
Mucin-producing neoplasms of the pancreas: an analysis of distinguishing clinical and epidemiologic characteristics. Clin Gastroenterol Hepatol (2009) 1.90
IgG4-related disease. Annu Rev Pathol (2013) 1.89
Kras(G12D) and p53 mutation cause primary intrahepatic cholangiocarcinoma. Cancer Res (2012) 1.83
IgG4-related systemic disease accounts for a significant proportion of thoracic lymphoplasmacytic aortitis cases. Arthritis Care Res (Hoboken) (2010) 1.83
A single heteroclitic epitope determines cancer immunity after xenogeneic DNA immunization against a tumor differentiation antigen. J Immunol (2003) 1.81
Pancreatic duct glands are distinct ductal compartments that react to chronic injury and mediate Shh-induced metaplasia. Gastroenterology (2009) 1.78
Implications of incidentally discovered, nonfunctioning pancreatic endocrine tumors: short-term and long-term patient outcomes. Arch Surg (2011) 1.78
FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience. Oncologist (2013) 1.76
Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. Clin Cancer Res (2006) 1.75
IgG4-related systemic disease as a cause of "idiopathic" orbital inflammation, including orbital myositis, and trigeminal nerve involvement. Surv Ophthalmol (2011) 1.75
Implications and management of pancreatic fistulas following pancreaticoduodenectomy: the Massachusetts General Hospital experience. Arch Surg (2008) 1.72
Direct medical costs of acute pancreatitis hospitalizations in the United States. Pancreas (2007) 1.71
Debridement and closed packing for sterile or infected necrotizing pancreatitis: insights into indications and outcomes in 167 patients. Ann Surg (2008) 1.69